Old Web
English
Sign In
Acemap
>
authorDetail
>
Coumaran Egile
Coumaran Egile
AstraZeneca
Oncology
Internal medicine
Lung cancer
Nausea
Adverse effect
3
Papers
1
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR -mutated, MET -amplified advanced non-small-cell lung cancer
2021
Investigational New Drugs
Jin-Ji Yang
Jian Fang
Yongqian Shu
Jianhua Chang
Gongyan Chen
Jianxing He
Wei Li
Xiao-Qing Liu
Nong Yang
Caicun Zhou
Jian An Huang
Melanie M. Frigault
Ryan J. Hartmaier
Ghada F. Ahmed
Coumaran Egile
Shethah Morgan
Remy B. Verheijen
Anders Mellemgaard
Liu Yang
Yi-Long Wu
Show All
Source
Cite
Save
Citations (1)
A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer.
2020
Investigational New Drugs
Jin-Ji Yang
Jian Fang
Yongqian Shu
Jianhua Chang
Gongyan Chen
Jianxing He
Wei Li
Xiao-Qing Liu
Nong Yang
Caicun Zhou
Jianan Huang
Melanie M. Frigault
Ryan J. Hartmaier
Ghada F. Ahmed
Coumaran Egile
Shethah Morgan
Remy B. Verheijen
Anders Mellemgaard
Liu Yang
Yi-Long Wu
Show All
Source
Cite
Save
Citations (0)
A Phase 1b Study of Savolitinib Plus Gefitinib for Patients with EGFR -Mutated MET -Amplified Advanced Non-Small-Cell Lung Cancer
2020
Social Science Research Network
Jin-Ji Yang
Jian Fang
Yongqian Shu
Jianhua Chang
Gongyan Chen
Jianxing He
Wei Li
Xiaoqing Liu
Nong Yang
Caicun Zhou
Jian An Huang
Melanie M. Frigault
Ryan J. Hartmaier
Ghada F. Ahmed
Coumaran Egile
Shethah Morgan
Remy B. Verheijen
Anders Mellemgaard
Liu Yang
Yi-Long Wu
Show All
Source
Cite
Save
Citations (0)
1